Sinclair raises funds to buy Solvay products as new CEO is revealed
This article was originally published in Scrip
Executive Summary
Sinclair Pharma is to acquire two dermatology products from Solvay Pharmaceuticals. It plans to sell shares to raise up to £25 million to fund the acquisition, although the equity fundraising could be scaled back if the company successfully negotiates a new debt facility.